Alvotech and Fuji Pharma have entered into a binding agreement for the Japanese company to have exclusive local commercialization rights to the biosimilar of Janssen’s Stelara (ustekinumab) human interleukin-12 and -23 antagonist that Alvotech is developing.
Under the terms of the agreement, Alvotech will assume responsibility for development and commercial supply from its manufacturing facility in...






